Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. Epub 2013 Apr 6. Review.

2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
4.
5.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
6.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
7.

Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.

Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.

Eur Neuropsychopharmacol. 2014 Dec;24(12):1873-84. doi: 10.1016/j.euroneuro.2014.09.013. Epub 2014 Oct 18.

PMID:
25453480
8.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
9.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
10.

Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Scott NG, Ripperger-Suhler J, Rajab MH, Kjar D.

J Child Adolesc Psychopharmacol. 2010 Jun;20(3):197-203. doi: 10.1089/cap.2009.0104.

PMID:
20578932
11.

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.

Value Health. 2008 May-Jun;11(3):376-88. doi: 10.1111/j.1524-4733.2007.00256.x.

12.

An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):485-92. doi: 10.1089/cap.2008.0125.

13.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
14.
16.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
17.

Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?

Niederhofer H.

Psychiatr Danub. 2009 Sep;21(3):330. No abstract available.

19.

Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.

Cunill R, Castells X, Tobias A, Capellà D.

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):961-9. doi: 10.1002/pds.3473. Epub 2013 Jul 1.

PMID:
23813665
20.

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.

Bushe CJ, Savill NC.

J Psychopharmacol. 2014 Mar;28(3):204-11. doi: 10.1177/0269881113478475. Epub 2013 Feb 25. Review.

PMID:
23438503

Supplemental Content

Support Center